Moderate to Severe Palmoplantar Psoriasis
1 clinical trials · Condition
◉ Watch Moderate to Severe Palmoplantar Psoriasis
| Record | Firm | Date |
|---|---|---|
| Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (NCT01806597) | Novartis Pharmaceuticals | 2013-06-19 |
Track Moderate to Severe Palmoplantar Psoriasis automatically
Every clearance here is in the API, with alerts when new ones post.